Bold Science

EvolveImmune’s proprietary immunobiologics platform delivers both sustained immune activation and tumor cell targeting in a single agent. Through integrated T cell signaling, EvolveImmune’s first-in-category biologics directly target tumor cells and provide potent, tissue-localized immune amplification at the tumor site to maximize tumor killing.

Transformative Outcomes

Our biotherapeutics are engineered to overcome limitations of conventional CD3 bispecifics and other immune therapies to offer a better future for our patients in need, by maximizing therapeutic benefit and minimizing toxicity.

EvolveImmune scientists have unlocked novel biotherapeutic T cell engager designs that unleash potent, differentiated T cell costimulation to prevent and rejuvenate CD8 T cell exhaustion.